DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

Of course, biotech stocks come with risks, too, such as never getting their flagship product through clinical testing or failing ... for unmet medical needs in HIV, oncology, and NASH, a type ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

She said domestic production of HIV commodities such as test kits and anti-retroviral drugs was part of measures government was taking to end AIDS as a public health threat by 2030. The NACA boss ...

The European Commission (EC) has authorized the combination of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) and Johnson & Johnson’s (NYSE: JNJ) Rekambys (rilpivirine long-acting ...

Trinity Biotech plc (NASDAQ:TRIB), an Ireland-based diagnostic company with a market capitalization of $23.7 million and current trading price of $1.32, is evaluating the potential effects of a recent ...

Although a temporary waiver for essential services was introduced on January 28, 2025, the impact on HIV testing programs using Trinity Biotech's products is uncertain. This pause may affect the ...